Bionano Genomics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bionano Genomics's operating margin was −116.95% for fiscal 2025.
View full Bionano Genomics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −116.95% | +220.92 pp |
| 2024 | 2024-12-31 | −337.87% | +258.11 pp |
| 2023 | 2023-12-31 | −595.98% | −122.28 pp |
| 2022 | 2022-12-31 | −473.70% | −44.91 pp |
| 2021 | 2021-12-31 | −428.79% | +24.59 pp |
| 2020 | 2020-12-31 | −453.38% | −197.94 pp |
| 2019 | 2019-12-31 | −255.44% | −85.33 pp |
| 2018 | 2018-12-31 | −170.12% | +74.16 pp |
| 2017 | 2017-12-31 | −244.28% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −88.34% | +27.51 pp |
| Q1 2026 | 2026-03-31 | −118.09% | +13.00 pp |
| Q4 2025 | 2025-12-31 | −107.36% | +38.92 pp |
| Q3 2025 | 2025-09-30 | −115.90% | +606.99 pp |
| Q2 2025 | 2025-06-30 | −115.85% | +103.15 pp |
| Q1 2025 | 2025-03-31 | −131.10% | +223.82 pp |
| Q4 2024 | 2024-12-31 | −146.28% | +86.46 pp |
| Q3 2024 | 2024-09-30 | −722.89% | +492.09 pp |
| Q2 2024 | 2024-06-30 | −218.99% | +234.00 pp |
| Q1 2024 | 2024-03-31 | −354.92% | +155.44 pp |
| Q4 2023 | 2023-12-31 | −232.74% | +224.07 pp |
| Q3 2023 | 2023-09-30 | −1,214.98% | −769.77 pp |
| Q2 2023 | 2023-06-30 | −452.99% | +27.95 pp |
| Q1 2023 | 2023-03-31 | −510.36% | +15.33 pp |
| Q4 2022 | 2022-12-31 | −456.81% | −0.07 pp |
| Q3 2022 | 2022-09-30 | −445.22% | −1.00 pp |
| Q2 2022 | 2022-06-30 | −480.94% | −53.66 pp |
| Q1 2022 | 2022-03-31 | −525.68% | −173.32 pp |
| Q4 2021 | 2021-12-31 | −456.74% | −177.80 pp |
| Q3 2021 | 2021-09-30 | −444.21% | +21.50 pp |
| Q2 2021 | 2021-06-30 | −427.28% | +201.74 pp |
| Q1 2021 | 2021-03-31 | −352.37% | +506.96 pp |
| Q4 2020 | 2020-12-31 | −278.94% | −22.14 pp |
| Q3 2020 | 2020-09-30 | −465.71% | −294.11 pp |
| Q2 2020 | 2020-06-30 | −629.02% | −314.35 pp |
| Q1 2020 | 2020-03-31 | −859.33% | −525.55 pp |
| Q4 2019 | 2019-12-31 | −256.80% | −104.85 pp |
| Q3 2019 | 2019-09-30 | −171.60% | +39.41 pp |
| Q2 2019 | 2019-06-30 | −314.67% | −196.31 pp |
| Q1 2019 | 2019-03-31 | −333.78% | −88.63 pp |
| Q4 2018 | 2018-12-31 | −151.95% | +31.46 pp |
| Q3 2018 | 2018-09-30 | −211.01% | — |
| Q2 2018 | 2018-06-30 | −118.35% | — |
| Q1 2018 | 2018-03-31 | −245.15% | — |
| Q3 2017 | 2017-09-30 | −183.41% | — |
Over the last five reported fiscal years, Bionano Genomics's operating margin increased from −453.38% to −116.95%, a change of +336.44 percentage points. The latest reported quarter, Q2 2026, shows −88.34%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bionano Genomics filings at SEC.gov ↗